MYCN, regulated by SEs, plays a key role in the tolerance of triple-negative breast cancer (TNBC) to neoadjuvant chemotherapy, where cells with high MYCN expression are more sensitive to BET inhibitors, such that the combined inhibition of BET and MEK produces a synergistic killing effect on TNBC cells [141]. Here, DNER is linked to triple-negative breast carcinoma.